Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fresenius Kabi Oncology

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

Gilead will file safer HIV combination before year-end

New version of Stribild is less likely to cause side effects

- PMLiVE

Janssen ‘extremely disappointed’ by NICE’s Olysio guidance

Hepatitis C drug only recommended use for one out of three licenced indications

Gilead Sciences

Gilead gets EU nod for cancer drug Zydelig

Approved for patients with chronic lymphocytic leukaemia and follicular lymphoma

- PMLiVE

Novo Nordisk’s Xultophy diabetes combo approved in Europe

Once-daily injection combines the firm's Tresiba and Victoza

- PMLiVE

Merck Serono pulls development of lung cancer prospect

Ditches tecemotide immunotherapy to focus on anti-PD1

- PMLiVE

FDA panel backs Novo Nordisk’s liraglutide for obesity

Committee says diabetes drug could be used to reduce weight

- PMLiVE

Pre-chemotherapy indication for Xtandi in prostate cancer

Astellas drug set to compete with J&J’s Zytiga

- PMLiVE

Pharma spent $342m on journal advertising in first half of 2014

J&J led spending and Invokana was most advertised brand

- PMLiVE

Liraglutide seems effective in obesity, says FDA reviewer

Novo Nordisk drug is already successful diabetes treatment

- PMLiVE

Merck brings first PD-1 inhibitor to US market

FDA approves Keytruda for advanced melanoma

- PMLiVE

Drug regulators collaborate to tackle Ebola outbreak

EMA and FDA team up with global partners to accelerate access to medicines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links